Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01136317

Acronym

Oberab

Enrollment

Unknown

Registered

2010-06-03

Start date

2010-04-01

Completion date

2010-07-01

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Reflux

Brief summary

This study aims to determine, in obese subjects, the antisecretory effect of a single dose of placebo, rabeprazole 20 mg and omeprazole 20 mg using 24h gastric pH monitoring, in a prospective, monocentre, randomized manner. Monitorings are separated between 6 and10 days. The main outcome criteria of analysis is the percentage of time with gastric pH above 3 during 24hours.

Interventions

DRUGOmeprazole

DRUGRabeprazole

DRUGLactose

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Helicobacter negative obese subject (BMI 30 to 40), * 18 to 55 years old, * normal hepatic biology and morphology (echography) * Contraceptive methods in women.

Exclusion criteria

* Subjects with previous abdominal surgery, with diabetic or immunosuppressive treatment.

Design outcomes

Primary

Measure	Time frame
In order to measure antisecretory effect, the main outcome criteria of analysis will be the percentage of time with gastric pH above 3 and measured during 24hours following rabeprazole administration in comparison with omeprazole administration.	—

Countries

France

Contacts

PRINCIPAL_INVESTIGATORStanislas Bruley des Varannes, MD

Nantes University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 15, 2026